

Art C1
in which A₁ and A₂ are amino acid sequences comprising 1 to 5 amino acids, with the exception of the peptides or polypeptides having one of the sequences:

- W-S-P-C-S-V-T-C-G- (SEQ ID NO. 2)
- W-S-S-C-S-V-T-C-G- (SEQ ID NO. 3)
- W-S-Q-C-S-V-T-C-G- (SEQ ID NO. 4)
- W-S-P-W-S-E-W-T-S-C-S-T-S-C-G-N-G-I-Q-Q-R-G-R (SEQ ID NO:15)
- W-S-H-W-S-P-W-S-S-C-S-V-T-C-G-D-G-V-I-T-R-I-R (SEQ ID NO:16)
- W-G-P-W-S-P-W-D-I-C-S-V-T-C-G-G-G-V-Q-K-R-S-R (SEQ ID NO:17)
- W-S-Q-C-S-V-Y-C-G (SEQ ID NO:18)
- T-E-W-S-A-C-S-K-S-C-G-M-G-F-S-T-R-V-T-N-R-N (SEQ ID NO:19)
- T-E-W-S-A-C-S-K-T-C-G-M-G-I-S-T-R-V-T-N-D-N (SEQ ID NO:20).

Seq 1 is not represented above where A1 is /-Seq 1

Not there?

method

Art C1
9. (Amended) Use of a peptide selected from the peptides according to one of Claims 1 to 7 and the peptides having the sequence:

- W-S-P-C-S-V-T-C-G- (SEQ ID NO. 2)
- W-S-S-C-S-V-T-C-G- (SEQ ID NO. 3)
- W-S-Q-C-S-V-T-C-G- (SEQ ID NO. 4)
- W-S-P-W-S-E-W-T-S-C-S-T-S-C-G-N-G-I-Q-Q-R-G-R (SEQ ID NO:15)
- W-S-H-W-S-P-W-S-S-C-S-V-T-C-G-D-G-V-I-T-R-I-R (SEQ ID NO:16)
- W-G-P-W-S-P-W-D-I-C-S-V-T-C-G-G-G-V-Q-K-R-S-R (SEQ ID NO:17)
- W-S-Q-C-S-V-Y-C-G (SEQ ID NO:18)
- T-E-W-S-A-C-S-K-S-C-G-M-G-F-S-T-R-V-T-N-R-N (SEQ ID NO:19)
- T-E-W-S-A-C-S-K-T-C-G-M-G-I-S-T-R-V-T-N-D-N (SEQ ID NO:20), for the manufacture of a medicine intended for the regeneration of the nervous system cells.

method

10. (Amended) Use of a peptide selected from the peptides according to one of Claims 1 to 7 and the peptides having the sequence:

- W-S-P-C-S-V-T-C-G- (SEQ ID NO. 2)
- W-S-S-C-S-V-T-C-G- (SEQ ID NO. 3)
- W-S-Q-C-S-V-T-C-G- (SEQ ID NO. 4)
- W-S-P-W-S-E-W-T-S-C-S-T-S-C-G-N-G-I-Q-Q-R-G-R (SEQ ID NO:15)
- W-S-H-W-S-P-W-S-S-C-S-V-T-C-G-D-G-V-I-T-R-I-R (SEQ ID NO:16)

A3
cont -T-E-W-S-A-C-S-K-T-C-G-M-G-I-S-T-R-V-T-N-D-N (SEQ ID NO:20), for the manufacture of a medicine intended for the treatment of neuroblastomas.

13. (Amended) Additive for the cellular cultures of nerve cells, characterized in that it comprises a peptide selected from the peptides according to one of Claims 1 to 7 and the peptides having the sequence:

- sub C1*
- W-S-P-C-S-V-T-C-G- (SEQ ID NO. 2)
 - W-S-S-C-S-V-T-C-G- (SEQ ID NO. 3)
 - W-S-Q-C-S-V-T-C-G- (SEQ ID NO. 4)
 - W-S-P-W-S-E-W-T-S-C-S-T-S-C-G-N-G-I-Q-Q-R-G-R (SEQ ID NO:15)
 - W-S-H-W-S-P-W-S-S-C-S-V-T-C-G-D-G-V-I-T-R-I-R (SEQ ID NO:16)
 - W-G-P-W-S-P-W-D-I-C-S-V-T-C-G-G-G-V-Q-K-R-S-R (SEQ ID NO:17)
 - W-S-Q-C-S-V-Y-C-G (SEQ ID NO:18)
 - T-E-W-S-A-C-S-K-S-C-G-M-G-F-S-T-R-V-T-N-R-N (SEQ ID NO:19)
 - T-E-W-S-A-C-S-K-T-C-G-M-G-I-S-T-R-V-T-N-D-N (SEQ ID NO:20).

A4 14. (Amended) Cellular expression vector, characterized in that it comprises a nucleic acid sequence expressing a peptide selected from the peptides according to one of Claims 1 to 7 and the peptides having the sequence:

- W-S-P-C-S-V-T-C-G- (SEQ ID NO. 2)
- W-S-S-C-S-V-T-C-G- (SEQ ID NO. 3)
- W-S-Q-C-S-V-T-C-G- (SEQ ID NO. 4)
- W-S-P-W-S-E-W-T-S-C-S-T-S-C-G-N-G-I-Q-Q-R-G-R (SEQ ID NO:15)
- W-S-H-W-S-P-W-S-S-C-S-V-T-C-G-D-G-V-I-T-R-I-R (SEQ ID NO:16)
- W-G-P-W-S-P-W-D-I-C-S-V-T-C-G-G-G-V-Q-K-R-S-R (SEQ ID NO:17)
- W-S-Q-C-S-V-Y-C-G (SEQ ID NO:18)
- T-E-W-S-A-C-S-K-S-C-G-M-G-F-S-T-R-V-T-N-R-N (SEQ ID NO:19)
- T-E-W-S-A-C-S-K-T-C-G-M-G-I-S-T-R-V-T-N-D-N (SEQ ID NO:20).

Please insert the Sequence Listing filed concurrently herewith following the abstract, and renumber pages 1-12 of the Sequence Listing as pages 17-28. Please also delete the Sequence Listing filed with the application.